Kids With Food Allergies (KFA) is sharing this press release from Aquestive Therapeutics to bring you the latest research news.

[PRESS RELEASE]

Aquestive Therapeutics Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen®

• AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
• AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
• Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
• End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
• Company hosts conference call at 8:00 am ET on September 27, 2022

WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film.

“Speed matters in delivering systemic epinephrine during an anaphylaxis event. Any delay can result in severe bronchospasm, acute respiratory failure and/or cardiovascular collapse, as well as less favorable outcomes and death,” said David Bernstein, MD, University of Cincinnati. “AQST-109 continues to demonstrate fast delivery of therapeutic levels which are necessary to stop anaphylaxis at an early stage and prevent progression to a more severe reaction.”

The EPIPHAST II trial was designed to compare single doses of AQST-109 to EpiPen® 0.3mg and epinephrine 0.3mg intramuscular (IM) injection, as well as repeat doses of AQST-109 to repeat doses of epinephrine 0.3mg IM injection. Results from the single dose administration showed AQST-109 achieved a significantly faster Tmax (12 minutes), compared to both EpiPen® (22.5 minutes) and epinephrine 0.3mg IM injection (45 minutes). AQST-109 repeat dosing provided significantly higher drug plasma concentrations, with a Tmax of 8 minutes after administration, and extensive absorption was observed. The mean maximum concentration (Cmax) of AQST-109 was 465 pg/mL after one dose and 2,958 pg/mL after two doses. In comparison, the epi 0.3mg IM injection Cmax was 489 pg/mL after one dose and 911 pg/mL after two doses. The single dose of EpiPen resulted in a Cmax of 869 pg/mL.

After one dose of AQST-109, maximum mean effects on systolic blood pressure occurred within 5 minutes of dosing compared to 8 minutes for EpiPen. Maximum mean effects in heart rate occurred within 8 minutes of administering AQST-109 compared to an average of 5 minutes within administering EpiPen. Safety results for AQST-109 were in line with expectations, and no severe or serious adverse events were reported.

“We are pleased to see that AQST-109 compared favorably to both the EpiPen and the epi 0.3mg IM injection across several measures,” said Daniel Barber, Chief Executive Officer of Aquestive. “This is a meaningful step forward for this program and brings us closer to improving the lives of people who are looking for alternatives to the current standard of care for allergic reactions. Literature suggests that over 40 million Americans are at risk for acute anaphylactic episodes. Yet, over half of those who have experienced anaphylaxis have never received an epinephrine auto-injector prescription. We believe AQST-109 will provide a meaningful addition to treating anaphylaxis and we look forward to sharing the full dataset with the FDA, which will be the basis for our end-of-Phase 2 meeting scheduled for the fourth quarter of 2022.”

About Anaphylaxis
Anaphylaxis is a serious systemic hypersensitivity reaction with rapid onset and potentially fatal. As many as 49 million people in the United States are at chronic risk for anaphylaxis. Lifetime prevalence is at least 5%, or more than 16 million people in the United States. Direct costs of anaphylaxis have been estimated at $1.2 billion per year, with direct expenditures of $294 million for epinephrine, and indirect costs of $609 million. The frequency of hospital admissions for anaphylaxis has increased 500-700% in the last 10-15 years. 52% of patients, who previously experienced anaphylaxis, had never received an epinephrine autoinjector prescription, and 60% did not have an autoinjector currently available. The most common causes of anaphylaxis are foods (such as peanuts), venom from insect stings, and medications. Epinephrine injection is the current standard of treatment intended to reverse the severe manifestation of anaphylaxis, which may include skin rash, throat swelling, respiratory problems, gastrointestinal distress, and loss of consciousness.

About AQST-109
AQST-109 is a polymer matrix-based epinephrine prodrug administered as a sublingual film that is applied under the tongue for the rapid delivery of epinephrine. The product is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for AQST-109 is thinner and smaller than an average credit card, can be carried in a pocket, and is designed to withstand weather excursions such as exposure to rain and/or sunlight.

About Aquestive Therapeutics
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products on the U.S. market, four licensed products and one stand-alone proprietary product to date, Sympazan® (clobazam) oral film for the treatment of seizures associated with Lennox-Gastaut syndrome. Our licensees market their products in the U.S. and around the world. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product pipeline focused on treating diseases of the central nervous system, or CNS, and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. For more information, visit Aquestive.com and follow us on LinkedIn.

Forward Looking Statement
Certain statements in this press release include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the advancement and related timing of AQST-109 through the regulatory and development pipeline and clinical and business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approvals of our product candidates; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution; sale of and demand for our products; our liquidity and availability of capital resources; customer demand for our products and services; customers’ ability to pay for goods and services; and ongoing availability of an appropriate labor force and skilled professionals. Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials for AQST-109 and our other product candidates; risk of delays in FDA approval of AQST-109, Libervant™ (diazepam) Buccal Film and our other drug candidates or failure to receive FDA approval; ability to address the concerns identified in the FDA’s Complete Response Letter dated September 25, 2020 regarding the New Drug Application for Libervant; risk of our ability to demonstrate to the FDA “clinical superiority” within the meaning of the FDA regulations of Libervant relative to FDA-approved diazepam rectal gel and nasal spray products including by establishing a major contribution to patient care within the meaning of FDA regulations relative to the approved products as well as risks related to other potential pathways or positions which are or may in the future be advanced to the FDA to overcome the seven year orphan drug exclusivity granted by the FDA for the approved nasal spray product of a competitor in the U.S. and there can be no assurance that we will be successful; risk that a competitor obtains FDA orphan drug exclusivity for a product with the same active moiety as any of our other drug products for which we are seeking FDA approval and that such earlier approved competitor orphan drug blocks such other product candidates in the U.S. for seven years for the same indication; risk in obtaining market access for other reasons; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risk of development of our sales and marketing capabilities; risk of sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer term liquidity and cash requirements and other cash needs, at the times and in the amounts needed; risks related to the outsourcing of certain marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance of our product and product candidates; the success of any competing products, including generics; risk of the size and growth of our product markets; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company’s products; risk of unexpected patent developments; the impact of existing and future legislation and regulatory provisions on product exclusivity; legislation or regulatory actions affecting pharmaceutical product pricing, reimbursement or access; claims and risks that may arise regarding the safety or efficacy of the Company's products and product candidates; risk of loss of significant customers; risks related to legal proceedings and associated costs, including patent infringement, investigative and antitrust litigation matters; changes in government laws and regulations; risk of product recalls and withdrawals; uncertainties related to general economic, political, business, industry, regulatory and market conditions and other unusual items; and other uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in our Annual Report on Form 10 K, in our Quarterly Reports on Form 10-Q, and in our Current Reports on Form 8-K filed with the Securities Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm®, Sympazan® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

The scary part of Halloween should be stories of witches and ghosts, not the candy. Food-centered holidays can be stressful when managing food allergies. With planning, your family can still safely enjoy Halloween traditions.

You can buy many allergy-friendly candies in stores and online. Also consider giving non-food treats, such as stickers or small toys. Many kids love them as much as candy, and they help avoid food allergy reactions.

Whether you are looking for allergy-friendly treats to hand out or for the “Switch Witch” to leave, below are some allergy-friendly Halloween candy ideas. These candies are free of milk, egg, soy, peanut, tree nuts, wheat, gluten, fish, and shellfish. Most candies are free from sesame and coconut, but not all.

Always read product labels to make sure treats are safe for your family. Some candies can be repackaged with other candies that may contain allergens. Be sure you know all of these label reading “tricks” to make sure your “treats” are safe:

• Different varieties of the same candy may have different ingredients.
• Different sizes of the same candy may have different ingredients or advisory labeling.
• Individually wrapped treats can be packaged in a larger bag. Make sure the inner and outer labels match.
• Repackaged candy may have different labels than the candy made and sold directly by the company.
• Be careful of products with claims like “allergy free” or “Halloween safe.” There is no such thing as an “allergy safe” or “allergy free” food because children can have allergies to any food. A food labeled “allergy free” may still include one of your child’s food allergens.
  
  

Amanda’s Own Chocolates – Any-occasion and seasonal chocolates including novelties, lollipops, and bars. Made without mustard, sulfites, and lupin.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Amore di Mona Chocolates – European dark chocolate and caramels made without corn, lupin, cane sugar, artificial colors, artificial flavors, and preservatives.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Bo & Ty Sweets Gummies and Sours – Gummy bears, gummy worms, sour bears, and sour worms in a variety of package sizes with an optional custom message. Package sizes include several party favor options.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Enjoy Life Chocolate Minis – Chocolate Minis with seasonal wrappers in bags containing 18 individually wrapped chocolate squares. Made without mustard, sulfites, lupin, artificial colors, and artificial flavors.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

free2b Chocolate Sunbutter Cups – Dairy-free chocolate cups filled with sunflower seed butter. Available in singles or two-pack.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

free2b Dark Chocolate Mint Cups – Dark chocolate cups with a creamy mint filling.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

free2b Sun Cups Minis – Dark chocolate or rice chocolate sunflower butter mini cups in a resealable bag.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Gimbal's Jelly Beans – Classic jelly beans in a variety of flavors.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Glee Gum – All-natural chewing gum. No artificial flavors, artificial colors, artificial sweeteners, or preservatives.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Ice Chips Candy – Sugar-free hard candy made with xylitol and natural flavors. Available in 6-ounce tins and 1-ounce pouches. Some flavors contain coconut oil.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), sesame, wheat, gluten, fish, shellfish

No Whey! Foods Choco NoNo’s – Milk and nut free mini candy-coated chocolate drops.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

No Whey! Foods Milkless Minis – Chocolate Minis with seasonal wrappers in bags containing 8 individually wrapped chocolate squares.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

No Whey! Foods PeaNot Cups – Mini milkless chocolate cups filled with sunflower butter.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

No Whey! Foods Chocolate Lollipops – Seasonal milk- and soy-free chocolate lollipops in a variety of shapes. Many combine white and dark chocolate.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

No Whey! Foods Halloween Chocolate Covered Pretzels – Individually wrapped chocolatey covered pretzels covered in bright orange sprinkles representing the shape of a jack-o-lantern.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

PASCHA Chocolate Bars – Bean-to-bar chocolates made in a dedicated facility free of top allergens.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Red Bird Candy Puffs –Traditional soft puffed candy treats. Available in traditional peppermint and a variety of other flavors available in bags, tubs, jars, and bulk.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Righteously Raw Chocolates – Raw organic chocolate bars and mini chocolate bites in a variety of flavors. Some varieties contain coconut.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), sesame, wheat, gluten, fish, shellfish

Spangler Saf-T Pops – Lollipops on a safety loop handle. Manufactured free from allergens but Spangler candies may be rebagged by other retailers and combined in the same package with items that are not allergen free. Check the package to see if the product came from a Spangler facility.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

St. Claire’s Organics – Organic mints, pastilles, and candies.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Strawberry Hill Grand Delights Handmade Lollipops – Handmade lollipops free from top allergens and made without corn syrup.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), wheat, gluten, fish, shellfish

Sunkist Fruit Gems – Fruit gummy candies in flavors including orange, lemon, pink grapefruit, raspberry, and lime.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, wheat, gluten, fish, shellfish

Surf Sweets Delish Fish – Raspberry- and assorted-flavored fish-shaped gummy candies.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Surf Sweets Gummy Bears – Gummy bears made with organic fruit juice concentrate and organic cane sugar.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Surf Sweets Gummy Worms – Gummy worms made with organic fruit juice concentrate and organic cane sugar.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Trader Joe’s Sunflower Seed Butter Cups – Dark chocolate sunflower seed butter cups.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

YumEarth Licorice – Organic gluten-free licorice in black licorice and fruit flavors.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

YumEarth Organic Chewys – Individually wrapped fruit-flavored chewy treats.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

YumEarth Organic Fruit Snacks – Gummy fruit snacks in assorted flavors. Also available as Gummy Bunnies in the spring and Halloween Gummy Fruits in the fall.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

YumEarth Organic Giggles – Chewy candy bites in a resealable package.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

YumEarth Organic Lollipops – Organic lollipops in year-round, spring packaging, and Halloween packaging.
Free from: milk, egg, soy, peanut, tree nuts (not including coconut), coconut, sesame, wheat, gluten, fish, shellfish

Download, print, and share this guide

Search for Allergy-Friendly Candy

You can also search our Allergy-Friendly Foods collection for candies and treats based on the allergens you need to avoid. Click the “Search” tab, adjust the options for what you want, then click the green “Search” button at the bottom of the form.

Other Ways to Buy Allergy-Friendly Candy

You can also find many options online at the Natural Candy Store. Their site allows you to filter and shop by allergens too.

Originally published October 2015. Updated October 2022.

Whole Foods Market Issues Allergy Alert for Zerto Fontal Cheese Sold in Connecticut, New Jersey, and New York

For Immediate Release

September 30, 2022

Contact Information

1-844-936-8255

Company Announcement

AUSTIN, TX (Sept. 30, 2022) Whole Foods Market is voluntarily recalling Zerto Fontal cheese from fifty-four stores in Connecticut, New Jersey and New York because the product contains egg lysozyme, an egg white protein, which is not declared on the product label. People who have an allergy or severe sensitivity to eggs run the risk of a serious or life-threatening allergic reaction if they consume these products.

The affected product was sold at Whole Foods Market locations in New York, Connecticut, and New Jersey. The products were located in the Specialty department and were packaged by the slice with Whole Foods Market scale labels. The affected products can be identified by the name “Zerto Fontal”, a product code of 20565300000, sell by dates of 9/21/2022 – 10/20/2022, and were available for purchase from 9/21/2022 through 9/29/2022.

All affected product has been removed from store shelves. The mislabeling issue was discovered by a customer complaint of illness.

Customers who purchased this product at Whole Foods Market can bring a valid receipt into stores for a full refund. Customers with additional questions can call 1-844-936-8255 daily between the hours of 6:00 a.m. and 12:00 a.m. CST.

Momyer Distribution Inc. Issues Allergy Alert on Undeclared Milk in Dark Chocolate Almonds

For Immediate Release

September 28, 2022

Contact Information

Momyer Distribution Inc
503-393-3136

Company Announcement

Momyer Distribution Inc of Salem, Oregon is recalling Dark Chocolate Almonds because they may contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product.

The Dark Chocolate Almonds were distributed in Oregon and Washington through retail markets including Safeway/Albertsons and Roths Fresh Market. The product is packaged in a 9.5oz plastic container and sold in the produce section of these retail markets. The best by date is printed above the UPC bar code on a label.

Product sold at Safeway/Albertsons is labeled as “PRODUCE” in large red letters and Dark Chocolate Almonds are in black text on the top label, UPC 0 19061 19371 2. Product being recalled has a Best By Date on or before 10/15/2023.

Product sold at Roths Fresh Market is labeled as Holly Hill Gourmet Snacks Dark Chocolate Almonds, UPC 0 08918 23018 2. Product being recalled has a Best By Date on or before 10/21/2023.

No illnesses have been reported to date.

The recall was initiated after it was discovered that product was distributed in packaging that did not reveal the presence of milk.

This recall is being made with the knowledge of the U.S. Food and Drug Administration.

Customers with a milk allergy or sensitivity who have purchased the affected product are urged not to consume the product and dispose of it or return it to their place of purchase for a full refund.

Consumers with questions may contact the company at 503-393-3136 between 8am-4pm PST.

Arcade Snacks Issues Allergy Alert on Undeclared Egg in Candy Corn

For Immediate Release

September 23, 2022

Contact Information

1-508-832-6300

Company Announcement

Arcade Snacks of Auburn, MA is recalling its 15 ounce packages of Candy Corn because they may contain undeclared egg. People who have allergies to egg run the risk of serious or life-threatening allergic reaction if they consume these products.

Candy Corn was distributed in Massachusetts and Connecticut at the following locations:

• Johnson Roadside Farm Market in Swansea, Massachusetts
• Donelan’s Supermarkets in Massachusetts
• Fieldstone Farm Market in Marion, Massachusetts
• Foodies in Massachusetts
• Windfall Market in Falmouth, Massachusetts
• Highland Park Market in Glastonbury, Connecticut

The product comes in a 15 ounce, clear plastic container marked with UPC #0 18586 00114 4 and a best by date of 3/8/2023 on the label on the back panel.

No illnesses have been reported to date in connection with this problem.

The recall was initiated after it was discovered that the egg-containing product was distributed in packaging that did not reveal the presence of egg.

Consumers who have purchased 15 ounce packages of Candy Corn are urged to return them to the place of purchase for a full refund. Consumers with questions may contact the company at 1-508-832-6300 Monday – Friday 8am – 5pm ET.

TreeHouse Foods Announces Voluntary Recall of Certain Tuscan Garden Restaurant Style Italian Dressing Due to Undeclared Wheat and Soy

For Immediate Release

September 24, 2022

Contact Information

Consumer Affairs
800-596-2902

Company Announcement

OAK BROOK, Ill. (September 23, 2022) – TreeHouse Foods, Inc. (NYSE: THS) is voluntarily recalling one lot of Restaurant Style Italian Dressing sold under the brand name Tuscan Garden.

This recall is being conducted because the product is labeled as Restaurant Style Italian Dressing, while some of the bottles may contain Asian Sesame Dressing. The Restaurant Style Italian Dressing label indicates the allergens egg and dairy are in the product while the Asian Sesame Dressing product contains the allergens soy and wheat. People who have an allergy or severe sensitivity to soy or wheat run the risk of serious or life-threatening allergic reaction if they consume this product.

Product was distributed nationwide through Aldi between August 23, 2022 and September 23, 2022.

The product at issue can be identified by the UPC number and best if used by date which can be found below the neck of the bottle.

• Tuscan Garden Restaurant Style Italian Dressing
  • Size: 16 oz
  • UPC #: 4099100074871
  • Best By: 08/10/2023

Photos of the affected product label can be found below. No other varieties or UPC numbers are included in this recall.

TreeHouse Foods discovered the issue after receiving two complaints from the store level. At this time, TreeHouse has not received any reports of an allergic reaction associated with this product.

Consumers who have purchased any of the above products are urged to dispose of or return the products to the place of purchase for a full refund. Consumers with any questions may call 800- 596-2902, Monday through Friday between 8:00 a.m. and 7:00 p.m. (EST).

ABOUT TREEHOUSE FOODS

TreeHouse Foods, Inc. is a leading manufacturer and distributor of private label packaged foods and beverages in North America. We have over 40 production facilities across the United States, Canada and Italy, and our vision is to be the undisputed solutions leader for custom brands for our customers. Our product portfolio includes shelf stable, refrigerated, frozen and fresh products, including baked goods (cookies, crackers, pretzels, refrigerated dough, frozen waffles, in-store bakery products and snack bars); beverages (broth, single serve hot beverages, ready-to-drink coffee, creamers and powdered drinks); and meal solutions (dressings, hot cereal, macaroni and cheese, pasta, pickles, sauces and side dishes). We have a comprehensive offering of packaging formats and flavor profiles, and we also offer natural, organic and preservative-free ingredients across almost our entire portfolio. Our purpose is to make high quality food and beverages affordable to all.

Additional information, including TreeHouse's most recent statements on Forms 10-Q and 10-K, may be found at TreeHouse's website, http://www.treehousefoods.comExternal Link Disclaimer.

Van Law Food Products Issues Allergy Alert on Undeclared Soy and Wheat in Product

For Immediate Release

August 29, 2022 ; September 23, 2022

Contact Information

Van Law Food Product, Inc
1- 844-936-8255

Company Announcement

VanLaw Food Products Inc. is expanding its recall of Whole Foods Market 365 Organic Creamy Caesar Dressing because it contains undeclared Soy and Wheat allergens. The recall is being expanded to include Whole Foods Market 365 Organic Creamy Caesar Dressing with a BEST IF USED BY DATE of SEP 21 22 through JUN 06 23 and incorrect UPC Code 99482-49027.

People who may have an allergy or severe sensitivity to Soy or Wheat run the risk of serious or life- threatening allergic reaction if they consume these ingredients. The recalled products were sold in the produce or dairy department and distributed nationwide through Whole Foods Markets. All affected product has been removed from store shelves.

No illnesses have been reported to date.

The recalls were initiated when it was discovered the products were distributed in packaging that did not reveal the presence of Soy and Wheat allergen. The problem was caused when the back label from another product was mistakenly put on the products being recalled.

Consumers who purchased Whole Foods Market 365 Organic Creamy Caesar Dressing bottles with these Used by Codes (UPC code 99482-49027) in 12oz glass bottles should discard the product and seek a refund at the point of sale. Consumers with additional questions can call 1-844-936-8255 between the hours of 7:00 am and 10:00 pm CST.

ORIGINAL ANNOUNCEMENT

Van Law Food Products Inc. is recalling Whole Foods Market 365 Organic Creamy Caesar Dressing because it contains undeclared Soy and Wheat allergens.

People with an allergy or severe sensitivity to Soy or Wheat run the risk of serious or life-threatening allergic reaction if they consume these Ingredients. The product was sold in the produce or dairy department and distributed in the states of Alabama, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New Jersey, New Mexico, New York, North Carolina, Ohio, South Carolina, Tennessee, Texas, Utah, Wisconsin, and Wyoming.

No illnesses have been reported to date.

The recall was initiated after it was discovered that the product was distributed in packaging that did not reveal the presence of Soy and Wheat allergen. Subsequent investigation indicates that the problem was caused when the back label from another product was mistakenly put on the product being recalled.

Consumers who purchased Whole Foods Market 365 Organic Creamy Caesar Dressing with UPC code 99482-49027 in 12oz glass bottles with a Best by date of 04/06/2023 should discard the product and seek a refund at the point of sale with receipt. Consumers with additional questions can call 1- 844-936-8255 between the hours of 7:00 am and 10:00 pm CST.

World Variety Produce, Inc. Voluntarily Recalls Select Lots of Melissa’s Dutch Red Potatoes with Dijon Mustard Sauce Because it Contains Undeclared Egg Allergens

For Immediate Release

September 21, 2022

Contact Information

World Variety Produce, Inc.
1-800-588-0151

Company Announcement

People with an allergy or severe sensitivity to Egg run the risk of serious or life-threatening allergic reaction if they consume this ingredient. The product was sold in the produce department and distributed in the states of Arizona, California, Florida, Iowa, Idaho, Kansas, Louisiana, Mississippi, Montana, New Jersey, Oklahoma, Texas, Utah, and Washington.

No illnesses have been reported to date.

Melissa’s Brand Dutch Red Potatoes with Dijon Mustard Sauce can be identified by the following descriptions:

Melissa’s Dutch Red Potatoes with Dijon Mustard Sauce

Consumers who have purchased Melissa’s Brand Dutch Red Potatoes with Dijon Mustard Sauce are urged to destroy and dispose of the recalled product. Consumers with questions may contact World Variety Produce, Inc. at 1-800-588-0151, Mon-Fri 7:00 AM–5:00 PM PST.

Systemic mastocytosis (SM) affects nearly 32,000 people in the United States. People with SM have too many abnormal mast cells that cause a wide range of symptoms, including rashes, shortness of breath, and/or anaphylaxis. SM symptoms can look like asthma and allergy symptoms.

Interested in learning more? Blueprint Medicines is offering an informational program about SM this fall. During each virtual program, you’ll hear from a doctor and a person who will share their experience managing SM. You’ll also be able to participate in a live Q&A session. With four programs to choose from, you can pick the date and time that works best for you.

REGISTER NOW

Event Schedule

• Sept. 22, 2022, at 8 p.m. ET
• Oct. 26, 2022, at 7 p.m. ET
• Nov. 16, 2022, at 8 p.m. ET
• Dec. 6, 2022, at 7 p.m. ET
  
  

Valley International Cold Storage Acquisition, LLC, Recalls Frozen Beef Products Due To Misbranding And Undeclared Allergens

For Immediate Release

September 17, 2022

Contact Information

Conagra Brands Inc.
Daniel Hare
312-549-5355
Daniel.Hare@conagra.com

Company Announcement

WASHINGTON, Sept. 17, 2022 – Valley International Cold Storage Acquisition, LLC, a Harlingen, Texas establishment, is recalling approximately 22,061 pounds of frozen beef products due to misbranding and undeclared allergens, the U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) announced today. The product contains milk, a known allergen, which is not declared on the product label.

The frozen products are labeled as Korean-Style Beef, but contain a chicken sausage and pepper product, which contains milk. These items were produced on July 22, 2022. The following products are subject to recall [view labels]:

• 9.25-oz. cartons labeled as “Healthy Choice POWER BOWLS Korean-Style Beef” with lot code “5246220320” and a “best if used by” date of 04-18-2023.

The products subject to recall bear establishment number “34622” on the end flap of the carton. These items were shipped to retail locations nationwide.           

The problem was discovered when the producing establishment notified FSIS that it had received consumer complaints that the Korean-Style Beef cartons contained a chicken-based product.

There have been no confirmed reports of adverse reactions due to consumption of these products. Anyone concerned about an injury or illness should contact a healthcare provider.

FSIS is concerned that some product may be in consumers’ freezers. Consumers who have purchased these products are urged not to consume them. These products should be thrown away or returned to the place of purchase.

FSIS routinely conducts recall effectiveness checks to verify recalling firms notify their customers of the recall and that steps are taken to make certain that the product is no longer available to consumers. When available, the retail distribution lists will be posted on the FSIS website at www.fsis.usda.gov/recalls.

Consumers with questions about the recall can contact the Conagra Consumer Care line at 800-672-8152. Members of the media with questions about the recall can contact Daniel Hare, Senior Director of Communications, Conagra Brands, Inc., at 312-549-5355 or Daniel.Hare@conagra.com.

Consumers with food safety questions can call the toll-free USDA Meat and Poultry Hotline at 888-MPHotline (888-674-6854) or live chat via Ask USDA from 10 a.m. to 6 p.m. (Eastern Time) Monday through Friday. Consumers can also browse food safety messages at Ask USDA or send a question via email to MPHotline@usda.gov. For consumers that need to report a problem with a meat, poultry, or egg product, the online Electronic Consumer Complaint Monitoring System can be accessed 24 hours a day at https://foodcomplaint.fsis.usda.gov/eCCF/.

FSIS Issues Public Health Alert For Chicken Entree Products Due To Misbranding And An Undeclared Allergen

For Immediate Release

September 16, 2022

Contact Information

Retail Compliance Manager of Tampa Bay Fisheries
Diana Butz
813-752-8883, extension 208

Company Announcement

WASHINGTON, Sept. 16, 2022 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert due to concerns that the raw, ready-to-cook chicken entrée products may contain egg, a known allergen, which is not declared on the finished product label. FSIS is issuing this public health alert to ensure that consumers with an allergy to eggs are aware that these products should not be consumed. A recall was not requested because the products are no longer available for purchase.

The bacon-cheddar chicken entree products were produced on Sept. 9, 2022. The following products are subject to the public health alert [view labels]:

• 12 oz. plastic wrapped metal containers containing “aprons READY TO COOK MEAL FOR ONE BACON-CHEDDAR SMOTHERED CHICKEN” with a use by date of 9/21/2022.

The products bear establishment number “P-48176” inside the USDA mark of inspection. These items were shipped to Publix locations in Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia.                     

The problem was discovered when the establishment notified FSIS that they received notification from their customer that an incorrect label was on the back of the plastic wrapped metal container. The label on the back of the product contains information related to a chicken cordon bleu product, which does not contain egg. The bacon cheddar chicken product contains egg.

There have been no confirmed reports of adverse reactions due to consumption of these products. Anyone concerned about an illness should contact a health care provider.

FSIS is concerned that some products may be in consumers’ refrigerators or freezers. Consumers with an egg allergy who have purchased these products are urged not to consume them. These products should be thrown away or returned to the place of purchase.

Consumers and members of the media with questions about the public health alert can contact Diana Butz, Retail Compliance Manager of Tampa Bay Fisheries, at 813-752-8883, extension 208.

Consumers with food safety questions can call the toll-free USDA Meat and Poultry Hotline at 888-MPHotline (888-674-6854) or live chat via Ask USDA from 10 a.m. to 6 p.m. (Eastern Time) Monday through Friday. Consumers can also browse food safety messages at Ask USDA or send a question via email to MPHotline@usda.gov. For consumers that need to report a problem with a meat, poultry, or egg product, the online Electronic Consumer Complaint Monitoring System can be accessed 24 hours a day at https://foodcomplaint.fsis.usda.gov/eCCF/.

Kids With Food Allergies (KFA) is sharing this press release from Bryn Pharma LLC to bring you the latest research news.

[PRESS RELEASE]

Bryn Pharma Announces Completion of its Pivotal Study Comparing UTULY™ Epinephrine Intranasal Spray vs. 0.3 mg Epinephrine Autoinjector for the Treatment of Anaphylaxis

Bryn also announces completion of its human factor program and congestion study

Raleigh, NC – September 13, 2022 – Bryn Pharma LLC, a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, announced today the completion of its pivotal study of UTULY™ (epinephrine nasal spray). The primary objective of the study was to evaluate whether the administration of UTULY could achieve a successful release profile with both short- and long-term pharmacokinetic (PK) and pharmacodynamic (PD) outcomes comparable to those seen with administration of the 0.3 mg epinephrine autoinjector (EpiPen, generic). Bryn intends to present study results at upcoming medical conferences.

Epinephrine autoinjectors are the most widely prescribed treatment in the outpatient setting for anaphylaxis. While effective, autoinjectors have several limitations, including cost, fear of needles and convenience, leading people to avoid carrying the recommended two autoinjectors. This puts patients at greater risk of severe complications during an allergic reaction.

“We are extremely encouraged with the results from our pivotal study comparing the needle-free UTULY nasal spray to the 0.3 mg IM autoinjector. Our findings have given us the confidence to move forward in the regulatory process. We are thrilled to be one step closer to improving the lives of people who live in fear of life-threatening allergic reactions and who are looking for alternatives to costly and cumbersome autoinjectors,” said David Dworaczyk, Ph.D., CEO of Bryn Pharma.

“Completion of this study is a key milestone in the evolution of the treatment for anaphylaxis. Our hope is that the clinical trial results from Bryn’s innovative nasal product will support UTULY as an effective, safe and practical alternative to autoinjectors,” said Melinda Braskett, M.D., Associate Medical Director of the Gores Family Allergy Center at Children’s Hospital Los Angeles, and Bryn Pharma Scientific Advisor.

About Anaphylaxis

Anaphylaxis is a serious, life-threatening allergic reaction. The most common anaphylactic reactions are to foods, insect stings, medication and latex. A major difference between anaphylaxis and other allergic reactions is that anaphylaxis typically involves more than one system of the body. Estimates of Americans at risk for anaphylaxis range from 3.29 million to 40.9 million. Early and fast administration of epinephrine (with quick uptake) using today’s most common method of delivery, the autoinjector (as opposed to a manual syringe which is used in a medical setting under the direct supervision of a doctor), is deemed critical to bringing the anaphylactic reaction under control. Because 30% of patients who develop anaphylaxis will require a second dose of epinephrine to control symptoms, practice parameters recommend that physicians provide patients with two autoinjectors. If not treated properly, anaphylaxis can be fatal. However, studies have shown that the majority of people at risk for anaphylaxis often do not carry two epinephrine autoinjectors due in part to size and cost of the products, putting patients at greater risk of severe complications during an allergic reaction.

About Bryn Pharma

Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com.

Forward Looking Statements

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the Company’s products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forwardlooking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the performance information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT:
Rebecca Novak Tibbitt
Rebecca@RNTCommunications.com